These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26772398)

  • 61.
    Yang R; Lu M; Ming L; Chen Y; Cheng K; Zhou J; Jiang S; Lin Z; Chen D
    Int J Nanomedicine; 2020; 15():9061-9074. PubMed ID: 33239874
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
    Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
    [TBL] [Abstract][Full Text] [Related]  

  • 63. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
    Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
    Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
    [No Abstract]   [Full Text] [Related]  

  • 64. Clinical implications of CD44+/CD24- tumor cell ratio in breast cancer.
    Liu C; Luo Y; Liu X; Lu P; Zhao Z
    Cancer Biother Radiopharm; 2012 Jun; 27(5):324-8. PubMed ID: 22702496
    [TBL] [Abstract][Full Text] [Related]  

  • 65. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    Yamaguchi J; Moriuchi H; Ueda T; Kawashita Y; Hazeyama T; Tateishi M; Aoki S; Uchihashi K; Nakamura M
    BMC Cancer; 2021 Apr; 21(1):434. PubMed ID: 33879104
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
    Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
    BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
    Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer.
    Suo HD; Tao Z; Zhang L; Jin ZN; Li XY; Ma W; Wang Z; Qiu Y; Jin F; Chen B; Cao Y
    Biomed Res Int; 2020; 2020():7575862. PubMed ID: 32766313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. miR-155 increases stemness and decitabine resistance in triple-negative breast cancer cells by inhibiting TSPAN5.
    Yang LW; Wu XJ; Liang Y; Ye GQ; Che YC; Wu XZ; Zhu XJ; Fan HL; Fan XP; Xu JF
    Mol Carcinog; 2020 Apr; 59(4):447-461. PubMed ID: 32096299
    [TBL] [Abstract][Full Text] [Related]  

  • 75. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Autophagy inhibits cancer stemness in triple-negative breast cancer via miR-181a-mediated regulation of ATG5 and/or ATG2B.
    Park JW; Kim Y; Lee SB; Oh CW; Lee EJ; Ko JY; Park JH
    Mol Oncol; 2022 May; 16(9):1857-1875. PubMed ID: 35029026
    [TBL] [Abstract][Full Text] [Related]  

  • 77. LIPH promotes metastasis by enriching stem-like cells in triple-negative breast cancer.
    Zhang Y; Zhu X; Qiao X; Gu X; Xue J; Han Y; Sun L; Cui M; Liu C
    J Cell Mol Med; 2020 Aug; 24(16):9125-9134. PubMed ID: 32618099
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1).
    Szafarowski T; Sierdziński J; Ludwig N; Głuszko A; Filipowska A; Szczepański MJ
    Eur J Pharmacol; 2020 Jan; 867():172837. PubMed ID: 31811857
    [TBL] [Abstract][Full Text] [Related]  

  • 79. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
    Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
    Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
    Oon ML; Thike AA; Tan SY; Tan PH
    Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.